The Authors Reply:  by Isakova, Tamara et al.
7. Cupisti A, Comar F, Benini O et al. Effect of boiling on dietary phosphate
and nitrogen intake. J Renal Nutr 2006; 16: 36–40.
8. Shimamura S, Tamura Y, Mizota T et al. Low-phosphorus whey protein
manufacturing method thereof, low-phosphorus purified whey
hydrolysate and manufacturing method thereof. US Patent Publication
428,129. Publication data: 9 June 1995.
9. Levin S, Winkelstein JA. Diet and infrequent peritoneal dialysis in chronic
anuric uremia. N Engl J Med 1967; 277: 619–624.
John T. Daugirdas1
1Department of Medicine, University of Illinois College of Medicine,
Chicago, Illinois, USA
Correspondence: John T. Daugirdas, Department of Medicine,
University of Illinois College of Medicine, Chicago, Illinois 60612, USA.
E-mail: jtdaugir@uic.edu
Kidney International (2010) 77, 929–930; doi:10.1038/ki.2010.52
The Authors Reply: We thank Daugirdas for his comments
in ‘Proposed controlled trials of phosphate reduction in CKD:
which whey should we go?’1 We agree that reducing dietary
phosphorus intake is an important strategy to control
phosphorus balance in renal failure that is worthy of testing
in randomized trials. Daugirdas’s interesting approach would
effectively dissociate phosphorus restriction from undesirable
protein restriction through the use of whey supplements and
through avoidance of foods with high phosphorus-to-protein
ratios, such as processed foods. In support of this proposal,
the feasibility of dietary counseling to reduce serum
phosphate levels in dialysis patients has been established by
a recent randomized trial.2 It is likely, however, that several
factors could limit the effectiveness and sustainability of
dietary phosphorus restriction alone. First, the lack of
accurate labeling of phosphorus content in food additives
and its inconsistency across speciﬁc manufacturers3 compli-
cates dietary counseling. Second, while the cost of whey may
be low, effective ongoing dietary counseling requires dedi-
cated and relatively costly nutritionists. Perhaps most
importantly, kidney disease is largely a disease of poverty,
which, under the strain of the recession, is deepening in the
United States. Impoverished dialysis patients, even those most
successfully counseled, will likely forgo healthy food choices
in favor of cheap prepared foods that are phosphorus-laden
and widely available. To beneﬁt the majority of patients, we
would therefore suggest a multipronged approach to reduce
phosphate levels in dialysis patients, involving both pharma-
ceutical and dietary interventions as suggested by Daugirdas.
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Non-infected hemodialysis
catheters are associated with
increased inflammation compared
with arteriovenous fistulas
To the Editor: We read with great interest the article by
Goldstein et al.,1 reporting that catheters may cause
inﬂammation independent of infection as compared with
arteriovenous (AV) ﬁstula use. The authors showed greater
levels of serum C-reactive protein (CRP) in patients dialyzed
with central catheters in contrast to AV ﬁstulas.
We wish to highlight a few important points. First, the
authors did not give any information about comorbidity status,
underlying primary renal disease, level of uremia, glycemic
control of diabetic patients, echocardiographic data, anthro-
pometric measures, or prealbumin and cholesterol concentra-
tions showing nutritional status and residual renal function
(RRF) at the start of hemodialysis. It is known that CRP is
affected not only by infection but also by many variables, such
as RRF, coronary heart disease, peripheral arterial disease,
malnutrition, and metabolic syndrome.2,3 Thus, it is very
difﬁcult to attribute high CRP levels solely to the presence of a
catheter unless these variables are appropriately controlled for.
Second, the authors measured only serum CRP concentra-
tions, did not include other inﬂammation markers, and took
measurements just twice in a 6-month period. CRP levels,
especially in the hemodialysis population, may ﬂuctuate; thus,
obtaining single CRP measurements may be misleading.4
Third, the catheter group involved desperate patients in
whom ﬁstula attempt had failed. Thus, there was no option
other than catheter use, of course after trying the ﬁstula at a
more proximal site and vascular grafts. The advantages of the
‘ﬁstula ﬁrst’ slogan have long been established for naive
patients. Hence, a call for ﬁstula ﬁrst for patients with failed
ﬁstulas seems inappropriate.
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